A complex composition of bifidobacterium i771, and application and product thereof

Abstract

A complex composition of bifidobacterium i771, its application and product. The complex composition comprises bifidobacterium i771, choline and phosphatidylserine. The active bifidobacterium i771 and the complex product comprising the active bifidobacterium i771 and choline, phosphatidylserine both have significant efficacy in improving cognition.

Description

Technical Field

[0001] This article relates to the field of microbial engineering technology, specifically to a compound composition containing Bifidobacterium bifidum i771, and more particularly to a composition that improves cognitive function and its application. Background Technology

[0002] Alzheimer's disease is a major health concern affecting the elderly in my country. Due to its insidious and progressive onset, only 15%-20% of Alzheimer's patients in my country receive diagnosis and treatment, meaning over 80% remain untreated. Furthermore, drug treatment primarily aims to alleviate symptoms and slow disease progression. Given the limited effectiveness of drug therapy, early non-drug interventions are crucial.

[0003] The "gut-brain axis" has been confirmed by many scholars as a research hotspot. Research on gut probiotics and screening for probiotics or probiotic combinations to intervene in brain function, thereby improving cognition and alleviating Alzheimer's disease, has both theoretical support and feasibility. Summary of the Invention

[0004] The following is an overview of the subject matter described in detail herein. This overview is not intended to limit the scope of the claims.

[0005] The first aspect of this application provides a compound composition containing Bifidobacterium bifidum i771, which can improve cognitive function and can be used as an adjunct support supplement for daily health care of the elderly and early intervention in the onset of Alzheimer's disease. The Bifidobacterium bifidum i771 was deposited on May 20, 2020, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCCNO.19855 and Latin name Bifidobacterium bifidum.

[0006] In one exemplary embodiment, the compound composition comprises Bifidobacterium bifidum i771, choline, and phosphatidylserine.

[0007] In one exemplary embodiment, the mass ratio of Bifidobacterium bifidum i771, choline, and phosphatidylserine is 1:(5-20):(5-20).

[0008] In one exemplary embodiment, the number of viable Bifidobacterium bifidum i771 per unit dose is 5 × 10⁻⁶. 10 -5×10 11 CFU.

[0009] In one exemplary embodiment, the daily intake of the Bifidobacterium bifidum i771 is 5 × 10⁻⁶.7 CFU-5×10 9 CFU.

[0010] In one exemplary embodiment, the daily intake of the Bifidobacterium bifidum i771 is 1 × 10⁻⁶. 9 CFU or 5×10 9 CFU.

[0011] In one exemplary embodiment, the daily intake of Bifidobacterium bifidum i771, choline, and phosphatidylserine is 5 × 10⁻⁶. 7 -5×10 9 CFU, 60-120mg and 60-120mg;

[0012] Preferably, the daily intake of Bifidobacterium bifidum i771, choline, and phosphatidylserine is 1×10⁻⁶. 9 CFU, 94.5 mg, and 99.4 mg.

[0013] A second aspect of this application provides a product comprising the above-described compound composition.

[0014] In one exemplary embodiment, the product is food, health product, probiotic agent, medicine, or pharmaceutical composition.

[0015] In one exemplary embodiment, the product is a formula milk powder for middle-aged and elderly people.

[0016] In one exemplary embodiment, the product is an instant probiotic powder.

[0017] A third aspect of this application provides the use of Bifidobacterium bifidum i771 or the above-described compound composition or product containing therein, the application including the use of Bifidobacterium bifidum i771 or the compound composition or product in the preparation of a product having improved cognitive function.

[0018] In one exemplary embodiment, the amount of Bifidobacterium bifidum i771 or the compound composition added to the product having improved cognitive function is 0.2% to 13% by weight.

[0019] In one exemplary embodiment, the number of viable Bifidobacterium bifidum i771 per unit dose is 5 × 10⁻⁶. 10 -5×10 11 CFU.

[0020] In one exemplary embodiment, the daily intake of the Bifidobacterium bifidum i771 is 5 × 10⁻⁶. 7 CFU-5×10 9 CFU.

[0021] In one exemplary embodiment, the daily intake of the Bifidobacterium bifidum i771 is 1 × 10⁻⁶. 9 CFU or 5×10 9 CFU.

[0022] In one exemplary embodiment, the improvement of cognitive function includes preventing, mitigating, and / or improving individual cognitive decline.

[0023] In one exemplary embodiment, the individual is diagnosed with Alzheimer's disease or early related symptoms or intellectual disability in children.

[0024] Compared with existing related technologies, this application has the following advantages:

[0025] Both active Bifidobacterium bifidum i771 and compound products containing active Bifidobacterium bifidum i771 with choline and phosphatidylserine have significant effects on improving cognition. Among them, the compound product of active Bifidobacterium bifidum i771 with choline and phosphatidylserine has a more significant effect on improving cognitive impairment.

[0026] Other features and advantages of this application will be set forth in the following description, and will be apparent in part from the description, or may be learned by practicing the application. Other advantages of this application can be realized and obtained by means of the solutions described in the description and the accompanying drawings. Attached Figure Description

[0027] The accompanying drawings are used to provide an understanding of the technical solutions of this application and constitute a part of the specification. They are used together with the embodiments of this application to explain the technical solutions of this application and do not constitute a limitation on the technical solutions of this application.

[0028] Figure 1 This refers to the percentage of time each group of mice spent in the original platform area during the first water maze test in Example 1.

[0029] Figure 2 This refers to the number of times each group of mice traversed the original platform location area in the first water maze test in Example 1;

[0030] Figure 3 This refers to the percentage of time each group of mice spent in the original platform location area during the second water maze test in Example 1.

[0031] Figure 4 The number of times each group of mice traversed the original platform location area in the second water maze test in Example 1. Detailed Implementation

[0032] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0033] The raw materials used in this application are all conventional products on the market.

[0034] Unless otherwise specified, all materials and reagents used in the embodiments of this invention are commercially available. Experimental methods not specifically described in the embodiments are generally performed under standard conditions or as recommended by the manufacturer.

[0035] In the example:

[0036] Bifidobacterium bifidum i771 was deposited on May 20, 2020, at the China General Microbiological Culture Collection Center, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, with accession number CGMCCNO.19855 and Latin name Bifidobacterium bifidum.

[0037] Commercial strains of Bifidobacterium bifidum JM-1114 and Bifidobacterium bifidum JM-1115 were provided by Junlebao Microbial Collection Center (JMCC) and isolated from the intestines of healthy infants.

[0038] Example 1

[0039] 1) Experimental materials

[0040] Sample preparation

[0041] Preparation method of Bifidobacterium bifidum compound product: choline (15mg / kg) + phosphatidylserine (16mg / kg) + active Bifidobacterium bifidum (2mg / kg), gavage volume is 0.5mL / animal, equivalent to a daily human intake of 94.5mg + 99.4mg + 1×10 9 CFU

[0042] laboratory animals

[0043] C57BL / 6 mice, male, 14 weeks old.

[0044] APP / PS1 mice, male, 14 weeks old.

[0045] The laboratory animals were provided by Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. (China), Certificate of Conformity: SCXK(Su)2018-0008.

[0046] Instruments, consumables and reagents

[0047] Disposable 5ml syringes (Shanghai Kangdelai, China), electronic analytical balance (Precisa12A, Precisa, Switzerland), pyrogen-free ultrapure water system (Millipo3150, Millipore, USA), mouse gavage syringes (Zhongke Life, China), electrically heated constant temperature water bath (HW-SY11-K P2, Beijing Changfeng Instrument Co., Ltd., China), centrifuge tubes (1.5ml, Wuxi Nice Life Science Co., Ltd., China), water maze apparatus (ACT-200A, Beijing Youcheng Biotechnology Co., Ltd., China).

[0048] Edaravone (M70800-5G, Sigma-Aldrich, USA).

[0049] 2) Experimental methods

[0050] Animal grouping and administration by gavage

[0051] 1. Mice were housed in an SPF-grade environment at a temperature of 23±2℃ and a humidity of 55±5%, with a 12-hour light-dark cycle. After 7 days of acclimatization, 100 mice were divided into 10 groups: control group, model group, positive drug group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, experimental group 5, experimental group 6, and experimental group 7, with 10 mice in each group. The control group used untreated male C57BL / 6 mice, while all other groups used male APP / PS1 mice with congenital cognitive impairment.

[0052] 2. Mice in each group were administered daily by gavage. Mice in the control group and model group were given an equal volume of physiological saline daily. Mice in the positive control group were given 3 mg / kg edaravone daily in physiological saline. This was done once daily for 42 consecutive days.

[0053] 3. Experimental group 1 was given live Bifidobacterium bifidum JM-1114 via gavage daily at a dose of 10 mg / kg, which translates to a daily intake of 5 × 10⁻⁶ mg / kg for humans. 9 CFU; Experimental group 2 was given live Bifidobacterium bifidum JM-1115 via gavage daily at a dose of 10 mg / kg, which translates to a daily intake of 5 × 10⁻⁶ CFU / kg for humans. 9 CFU; the experimental group 3 received daily oral gavage with live Bifidobacterium bifidum i771 at a dose of 10 mg / kg, which translates to a daily intake of 5 × 10⁻⁶ CFU / kg for humans. 9 CFU. Once daily for 42 consecutive days.

[0054] 4. Experimental group 4 received a compound product via gavage daily. The specific components were choline + PS (phosphatidylserine) + active Bifidobacterium bifidum JM-1114, at doses of 15 mg / kg + 16 mg / kg + 2 mg / kg, which translates to a daily intake of 94.5 mg + 99.4 mg + 1 × 10⁻⁶ mg / kg for humans. 9 CFU; Experimental group 5 was given a compound product by gavage daily, specifically consisting of choline + PS (phosphatidylserine) + active Bifidobacterium bifidum JM-1115, at doses of 15 mg / kg + 16 mg / kg + 2 mg / kg, which translates to a daily intake of 94.5 mg + 99.4 mg + 1 × 10⁻⁶ mg / kg for humans. 9 CFU. Once daily for 42 consecutive days. Experimental group 6 received a compound product via gavage daily, specifically consisting of choline + PS (phosphatidylserine) + active Bifidobacterium bifidum i771, at doses of 15 mg / kg + 16 mg / kg + 2 mg / kg, equivalent to a daily intake of 94.5 mg + 99.4 mg + 1 × 10⁻⁶ CFU. 9 CFU.

[0055] 5. Experimental group 7 was given choline and phosphatidylserine by gavage daily at doses of 15 mg / kg + 16 mg / kg, which translates to a daily intake of 94.5 mg + 99.4 mg for humans.

[0056] Water Maze Experiment Training and Testing

[0057] 1. Twenty-four hours after the last gavage, each group began water maze training: each mouse was trained 4 times a day, each time entering the pool from a different quadrant of the water maze. The training ended when the mouse found the underwater platform or remained there for 60 seconds. Each training session was 15 minutes apart and continued for 4 days.

[0058] 2. After 4 days of training, the water maze test will begin on the 5th day: each mouse will be tested 4 times, each time starting from a different quadrant of the water maze and entering the pool (without a platform). The movement trajectory of the mice will be recorded within 120 seconds, and the percentage of time spent in the original platform area and the number of times the mice cross the original platform area will be analyzed.

[0059] 3. After completing the first water maze training and testing, the mice in each group continued to be administered the tested probiotics and compound products by gavage once a day for two consecutive weeks.

[0060] 4. After two weeks of gavage, repeat the water maze training and testing in steps 1 and 2 above for each group. Record and analyze the percentage of time each group of mice spent in the original platform area within the 120s test time and the number of times they crossed the original platform area during the second water maze test.

[0061] 3) Experimental Results

[0062] Efficacy evaluation of active probiotics and their compound products in improving cognition

[0063] 1. Active Bifidobacterium bifidum i771 and its compound products with choline and phosphatidylserine have the effect of improving cognitive impairment. Specifically, it can increase the proportion of time spent in the original platform area in the water maze test of APP / PS1 congenital cognitive impairment mice (p<0.01) and increase the number of times the original platform area is crossed (p<0.01). Among them, after the first experiment, the proportion of time spent in the original platform area in the active Bifidobacterium bifidum i771 group and the i771 combination group (choline + phosphatidylserine + active Bifidobacterium bifidum) was significantly different from that in the model group. See details. Figures 1 to 2 ,in, Figures 1 to 2 In the study, compared with the blank control group, **p<0.01; compared with the model control group, #p<0.05, ##p<0.01.

[0064] 2. To verify efficacy, the same test was performed after another 2 weeks of feeding. The results are shown below. Figures 3 to 4 Among them, the active Bifidobacterium bifidum i771 group and the i771 combination group showed **p<0.01 compared with the blank control group; and #p<0.05 and ##p<0.01 compared with the model control group.

[0065] 4) Experimental Conclusions

[0066] Under the experimental conditions, both active Bifidobacterium bifidum i771 and the compound product containing active Bifidobacterium bifidum i771 with choline and phosphatidylserine showed significant effects in improving cognition. Among them, the compound product containing active Bifidobacterium bifidum i771 with choline and phosphatidylserine showed more significant effects in improving cognitive impairment.

[0067] Verification has shown that the component ratios within the scope of this application have similar effects to those in Example 1.

[0068] Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of this application.

Claims

1. A compound composition for improving cognitive function, characterized in that, The compound composition consists of active Bifidobacterium bifidum i771, choline, and phosphatidylserine. Bifidobacterium bifidum i771 was deposited on May 20, 2020, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO. 19855. Its Latin name is [missing information]. Bifidobacterium bifidum ; The mass ratio of Bifidobacterium bifidum i771, choline and phosphatidylserine is 1:(5-20):(5-20).

2. The compound composition for improving cognitive function according to claim 1, characterized in that, The viable count of Bifidobacterium bifidum i771 per unit dose is 5 × 10⁻⁶. 10 -5×10 11 CFU.

3. The compound composition for improving cognitive function according to claim 1 or 2, characterized in that, The daily intake of choline and phosphatidylserine from the Bifidobacterium bifidum i771 strain is 5 × 10⁻⁶. 7 -5×10 9 CFU, 60-120mg and 60-120mg.

4. The compound composition for improving cognitive function according to claim 3, characterized in that, The daily intake of Bifidobacterium i771, choline, and phosphatidylserine is 1×10⁻⁶. 9 CFU, 94.5 mg, and 99.4 mg.

5. A product that improves cognitive function, characterized in that, The product with improved cognitive function comprises any one of the compound compositions with improved cognitive function according to claims 1 to 4.

6. The product with improved cognitive function according to claim 5, characterized in that, The products that improve cognitive function are health supplements.

7. The use of the compound composition with improved cognitive function according to any one of claims 1 to 4 or the product with improved cognitive function according to any one of claims 5 to 6 in the preparation of health products with improved cognitive function.

8. The application according to claim 7, characterized in that, The compound composition is added to the health product for improving cognitive function at a weight percentage of 0.2% to 13%.

Images